Clinical Trial Update: Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus. [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating whether pioglitazone plus metformin affects cardiovascular risk in insulin-treated type 2 diabetes mellitus patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)
• metformin (metformin)

Snippet

Sponsor: Takeda | Conditions: Diabetes Mellitus | Phase 4 | Status: COMPLETED